Toposar100 mg/5 ml

Toposar is a cytotoxic chemotherapy agent used, always as part of physician-supervised combination regimens, for the following malignancies:

FDA-approved indications (used in combination with other approved chemotherapeutic agents)

• Refractory testicular tumors — in patients who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic treatment.
• Small cell lung cancer (SCLC) — as first-line combination therapy with a platinum agent (e.g., cisplatin or carboplatin).

Guideline-supported / widely accepted uses (may be considered off-label but standard of care)

• Hodgkin lymphoma and non-Hodgkin lymphoma (as part of multi-agent regimens).
• Acute myeloid leukemia (AML), particularly in relapsed/refractory or transplant-conditioning settings.
• Ewing sarcoma and neuroblastoma in pediatric oncology protocols.
• Gestational trophoblastic neoplasia.
• Conditioning regimens prior to autologous/allogeneic stem cell transplantation.
• Hemophagocytic lymphohistiocytosis (HLH), used per established HLH treatment protocols.

Toposar must always be prescribed and administered by, or under the direct supervision of, a qualified oncologist experienced in the use of cancer chemotherapeutic agents. Toposar is not indicated for any non-oncologic condition.

Etoposide is available as a sterile injectable solution, typically containing 20 mg of Etoposide per mL for intravenous infusion after dilution. In some markets Etoposide is also available as an oral capsule (commonly 50 mg per capsule). Exact strength and available dosage form(s) may vary by manufacturer and market; confirm the specific pack composition on the product label before use.

Toposar is a semisynthetic derivative of podophyllotoxin, a compound originally derived from the mandrake plant (Podophyllum).It belongs to the class of antineoplastic agents known as topoisomerase II inhibitors and is used as part of combinationchemotherapy for several malignant tumors.

Toposar works by damaging DNA within rapidly dividing cancer cells, which halts cell division and leads to cell death.Because it affects both malignant and normal rapidly dividing cells, Toposar therapy requires close medical supervision,particularly of blood counts.

Antineoplastic agent (cytotoxic chemotherapy); Topoisomerase II inhibitor; Podophyllotoxin derivative. Toposar is classified under plant-alkaloid-derived anticancer drugs.

Mechanism

Etoposide inhibits the enzyme topoisomerase II, which is required for DNA strand religation during replication. By stabilizingthe normally transient topoisomerase II–DNA cleavable complex, Etoposide causes persistent DNA strand breaks, arresting cellsin the late S/early G2 phase of the cell cycle and triggering apoptosis in susceptible tumor cells.

Pharmacokinetics

• Bioavailability (oral): Highly variable, approximately 25–75% (average ~50%); oral dose is generally about double the equivalent IV dose.
• Protein binding: Approximately 94–97%, mainly to albumin.
• Metabolism: Partly hepatic (CYP3A4-mediated), with a significant fraction excreted unchanged.
• Elimination: Renal (about 35–50% excreted unchanged in urine) and biliary/fecal routes; elimination half-life is approximately 4–11 hours in adults with normal organ function.
• Renal/hepatic impairment: Clearance is reduced, requiring dose adjustment (see Dosage and Administration).

Toposar injection is intended for intravenous use only and must never be given intramuscularly, subcutaneously, intrathecally, or as a rapid IV bolus.

• Dilute the Toposar injection concentrate to the manufacturer-specified concentration using an appropriate compatible IV fluid (e.g., 0.9% sodium chloride or 5% dextrose) before administration.
• Administer as a slow intravenous infusion, typically over 30 to 60 minutes, to minimize the risk of hypotension and infusion-related reactions.
• Monitor blood pressure during infusion; slow or temporarily stop the infusion if hypotension develops.
• Avoid extravasation; Toposar is an irritant and can cause local tissue injury if it leaks outside the vein.
• Toposar must be prepared and administered under the supervision of healthcare professionals trained in the safe handling of cytotoxic chemotherapy agents, using appropriate protective precautions.
• Oral capsules, where used, are taken exactly as prescribed, generally on an empty stomach or as directed, at the same time each day of the treatment cycle.

Clinically significant interactions with Toposar include:

• Cisplatin: Prior or concurrent cisplatin therapy can reduce Toposar clearance, increasing the risk of myelosuppression and other toxicities; doses are adjusted within combination protocols to account for this.
• Cyclosporine (high-dose): Significantly increases Toposar plasma concentrations, raising the risk of toxicity; dose adjustment and close monitoring are required if co-administered.
• Warfarin and other anticoagulants: Toposar may potentiate anticoagulant effect, increasing bleeding risk; INR should be monitored more frequently.
• CYP3A4 inducers (e.g., phenytoin, phenobarbital): May increase Toposar clearance and reduce its efficacy; phenytoin has also been associated with increased seizure risk in some settings when used with chemotherapy agents.
• Live vaccines: Should be avoided during Toposar therapy because of the risk of disseminated infection in an immunosuppressed patient.
• Other myelosuppressive drugs or radiotherapy: Concomitant use increases the risk of additive bone marrow suppression and requires closer blood count monitoring.

Always inform the treating physician of all other medications, supplements, and vaccines before starting Toposar.

Side effects of Toposar range from very common and expected (requiring monitoring) to rare but serious.

Very common / common

• Myelosuppression — leukopenia, neutropenia, thrombocytopenia, and anemia (dose-limiting; usually reversible and nadir around days 7–14).
• Alopecia (hair loss), usually reversible after treatment ends.
• Nausea and vomiting.
• Mucositis / stomatitis, diarrhea, loss of appetite.
• Fatigue, transient elevation of liver enzymes.

Less common / serious

• Anaphylactic-like reactions during infusion — hypotension, bronchospasm, dyspnea, facial or tongue swelling, flushing, chills, fever (see Precautions and Warnings).
• Peripheral neuropathy.
• Secondary leukemia (treatment-related acute myeloid leukemia), a recognized long-term risk with cumulative Toposar exposure, especially in combination regimens.
• Hepatotoxicity.
• Local irritation or tissue injury with extravasation.

Patients should promptly report fever, unusual bruising/bleeding, severe mouth sores, breathing difficulty, or signs of infection to their oncology team.

Pregnancy: Toposar can cause fetal harm and has demonstrated embryo-fetal toxicity and mutagenic potential instudies. Toposar should be strictly avoided during pregnancy, particularly in the first trimester. If Toposar is considered essentialduring pregnancy, the patient must be counseled on the potential risk to the fetus, and use should occur only underspecialist oncology and maternal-fetal medicine guidance, with the potential benefit clearly justifying the potential risk.Women of reproductive potential should use effective contraception during and for a period after treatment; men receiving Toposarshould also use effective contraception, as advised by their physician.

Lactation: It is not known whether Toposar is excreted in human breast milk, but given its cytotoxic nature,breastfeeding is not recommended during Toposar therapy and generally should not resume until specifically advised safe by thetreating physician after therapy ends.

Always consult the treating oncologist before considering pregnancy, breastfeeding, or fertility preservation in relation to Toposar therapy.

Boxed warning: Myelosuppression

Toposar causes severe, dose-limiting myelosuppression that can be fatal. Toposar must be administered only under the supervision of aphysician experienced in the use of cytotoxic chemotherapy, with access to diagnostic and treatment facilities for managingbleeding and infectious complications. Complete blood counts must be monitored frequently before and during each treatment cycle,and doses should be withheld or adjusted for significant myelosuppression.

Anaphylactic-like reactions

Anaphylactic-like reactions, including hypotension, bronchospasm, dyspnea, and facial or tongue swelling, may occur duringor shortly after Toposar infusion, especially with rapid intravenous administration. Toposar must always be given as a slow,rate-controlled infusion, with resuscitation equipment and medications readily available, and vital signs monitored throughout.

Secondary malignancy

Treatment-related acute myeloid leukemia has been reported with Toposar, particularly with cumulative dosing and combination regimens;patients should be counseled about this long-term risk.

Other precautions

• Use caution in patients with hepatic or renal impairment (dose adjustment required — see Dosage and Administration).
• Avoid extravasation; Toposar is a tissue irritant.
• Live vaccines should be avoided during therapy due to immunosuppression.
• Toposar is mutagenic and potentially carcinogenic; handle and dispose of according to institutional cytotoxic drug safety procedures.
• Use only under specialist oncology supervision; not for self-administration or use outside a monitored chemotherapy setting.

Overdose of Toposar can cause severe, potentially life-threatening myelosuppression, severe mucositis, and metabolic acidosis.There is no specific antidote for Toposar overdose.

If Toposar overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away.Management in a hospital setting typically involves supportive care, including close monitoring of blood counts, prophylaxis ortreatment of infection, blood product support, and general supportive measures as directed by the treating medical team.Do not attempt to manage a suspected Toposar overdose at home.

Store Toposar injection vials at room temperature (below 30°C), protected from light, and do not freeze (freezing may cause precipitation). If oral Toposar capsules are dispensed, store them in a refrigerator (2–8°C) unless the product label specifies otherwise, and protect from light and moisture. Keep all Toposar products out of reach of children, and dispose of unused cytotoxic medicine according to local hazardous pharmaceutical waste guidance rather than household trash.

• Renal impairment: Dose reduction is required based on creatinine clearance (see Dosage and Administration); monitor renal function during treatment.
• Hepatic impairment: Dose reduction or withholding Toposar may be needed with significant hepatic dysfunction; liver function should be monitored.
• Elderly: May have reduced renal/hepatic reserve and greater sensitivity to myelosuppression; use with close monitoring and consider dose adjustment based on organ function.
• Pediatric patients: Used in specific pediatric oncology and HLH protocols with weight/BSA-based dosing under pediatric oncology supervision (see Pediatric Uses).
• Immunocompromised patients: Increased risk of infection due to combined disease- and treatment-related immunosuppression; live vaccines should be avoided.

The duration of Toposar therapy is determined entirely by the treating oncologist according to the specific combinationprotocol, cancer type, response to treatment, and tolerability. Toposar is typically given in cycles (for example, over3–5 consecutive days), with treatment cycles repeated every 3 to 4 weeks. The total number of cycles (commonly 3 to 6, or asrequired by the specific protocol, such as stem cell transplant conditioning or long-term maintenance in certain lymphoma orleukemia regimens) is individualized based on tumor response, blood counts, and overall tolerance. Toposar should never becontinued, stopped, or restarted without explicit instruction from the treating oncology team.

Antineoplastic agents; Topoisomerase II inhibitors; Podophyllotoxin (plant alkaloid) derivatives — Etoposide belongs to this pharmacologic class.

Etoposide exerts its cytotoxic effect by inhibiting topoisomerase II, an enzyme essential for relaxing supercoiled DNA andresealing DNA strand breaks during replication and transcription. Etoposide stabilizes the topoisomerase II–DNA cleavable complex,preventing re-ligation of the DNA strands. This results in the accumulation of irreparable double-strand DNA breaks, cellcycle arrest in the late S/G2 phase, and ultimately programmed cell death (apoptosis) in rapidly dividing malignant cells.

D

Toposar is used in pediatric oncology as part of established multi-agent chemotherapy protocols for malignancies such asneuroblastoma, Ewing sarcoma, Hodgkin and non-Hodgkin lymphoma, acute myeloid leukemia, and hemophagocytic lymphohistiocytosis(HLH), typically following published cooperative-group protocols (e.g., HLH-94/HLH-2004 for HLH). Dosing in children iscalculated by body surface area (or, in infants under 12 months or less than 10 kg, sometimes adjusted per body weight)according to the specific protocol used.

Toposar should be administered to pediatric patients only by, or under the direct supervision of, a pediatric oncologist,with close monitoring of blood counts, growth, and organ function. Safety and efficacy for indications outside establishedpediatric oncology protocols have not been established, and Toposar is not intended for use in any pediatric non-oncologic condition.